Ocugen, Inc. OCGN
0.96 USD +0.01 (+1.09%)
At closeNov 12, 2026, 4:07 AM EST
0.96 0.00 0.00%
Pre-market · Nov 12, 4:07 AM ET
0.9115 Day range 1.01
0.691 52-week range 2.73
- YTD
- -28.86%
- 1 year
- -28.33%
News
globenewswire.com Ocugen and Celairis Therapeutics Enter into Exclusive License Agreement for OCU400 in Australia, New Zealand, and ASEAN MALVERN, Pa. and SYDNEY, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, and…
zacks.com Ocugen's Q3 Earnings Match Estimates, Revenues Beat, Stock Rises OCGN's Q3 revenues beat estimates. Shares surge 17.4%.
benzinga.com UPDATE: Ocugen Q3 Adj. EPS $(0.06), Inline, Sales $1.951M Beat $1.098M Estimate Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.06) per share which met the analyst consensus estimate. This is a 14.29 percent increase over losses of $(0.07) per share from the same period…
benzinga.com Ocugen Q3 2026 Earnings Call Transcript Ocugen (NASDAQ:OCGN) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide real-time…
benzinga.com Ocugen Q3 EPS $(0.01) Beats $(0.06) Estimate, Sales $1.951M Beat $1.098M Estimate Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.06) by 83.33 percent. This is a 85.71 percent increase over losses of $(0.07) per…- benzinga.com Ocugen Executes Licensing Agreement With Roots Pharma And Its Strategic Partner Al-Dhow International For Exclusive Rights To OCU400 For Treatment Of Retinitis Pigmentosa In Middle East And North Africa Region Establishes strategic commercial reach across the Middle East and North Africa, advancing Ocugen’s goal of enabling global patient access to potentially transformational gene therapiesExpands access…